Skip to Content

Newsroom

Multi-Modality Therapy Increases Survival Rates For Early Stage Lung Cancer Patients

Multi-Modality Therapy Increases Survival Rates For Early Stage Lung Cancer Patients
M. D. Anderson News Release 05/14/01

A study led by Dr. Katherine M. W. Pisters, associate professor of thoracic/head and neck oncology, at The University of Texas M. D. Anderson Cancer Center, shows the use of Taxol®(paclitaxel) plus Paraplatin® (carboplatin for injection) administered before surgery is safe, effective and leads to favorable survival in early stage non-small cell lung cancer patients. The study, the Bimodality Lung Oncology Team (BLOT) trial, showed patients treated with this regimen had a one-year survival rate of 85 percent and a two-year survival rate of 65 percent, which are superior to historical controls.

“We need to develop treatment strategies that will improve survival outcomes," said Dr. Pisters. “Based on the results and feasibility of this study, we see encouraging survival rates for early stage non-small cell lung cancer patients. A randomized trial (S9900) is now under way in the United States comparing this approach of paclitaxel plus carboplatin followed by surgery to surgery alone. If this trial finds a survival benefit, the standard of care will change for patients with early stage non-small cell lung cancer.

5/14/01


© 2014 The University of Texas MD Anderson Cancer Center